SL Science Holding Ltd
SLBT | NASDAQ
$1.24
+$0.07 (+5.98%)
At close: Oct 30, 2026, 3:59 PM ET
$1.27
+$0.03 (+2.42%)
Pre-market:
Nov 2, 2026, 7:21 AM ET
Company Profile
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.
Key Executives
| Name | Position |
|---|---|
| Ching-Dong Wang | Founder, Chairman & CEO |
| Ethan Shen | CTO & Director |
| Ray Leung | CFO & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 01, 2026 | SC 13D/A | [Amend] Filing |
| Oct 01, 2026 | 4 | Filing |
| Sep 24, 2026 | 6-K | Filing |
| Sep 01, 2026 | 4 | Filing |
| Sep 01, 2026 | 6-K | Filing |
| Aug 27, 2026 | 6-K | Filing |
| Aug 14, 2026 | 424B3 | Filing |
| Aug 12, 2026 | EFFECT | Filing |
| Jul 31, 2026 | F-1 | Filing |
| Jul 10, 2026 | 6-K | Filing |
SL Science Holding Ltd
| Country | United States |
| IPO Date | Feb 5, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | William Wang |
Contact Details
No. 479, Chongyang Rd. Taipei,
New York 115010 United States
Stock Details
| Ticker Symbol | SLBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002070534 |
| CUSIP Number | G8191L116 |
| ISIN Number | KYG8191L1169 |
| SIC Code | 2836 |
Recent News
- 2 months ago / seekingalpha.comSL Science: A $1.15 Billion Valuation Built On Preclinical Promises
- 2 months ago / globenewswire.comSL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
- 2 months ago / globenewswire.comSL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform
Add to Watchlist
Select watchlists to add or remove SLBT